“As sponsor of the NHS clinical trial, I view the Axion extracorporeal cancer treatment device as a potential breakthrough. It combines scientific innovation with clinical relevance and the scalability required for real-world adoption… Axion enters its trial phase with the right foundation to achieve both measurable clinical impact and long-term investor value.”

“Its ability to target circulating tumour cells and pathogens without relying on systemic drugs is not only clinically significant, but strategically aligned with global priorities to reduce toxicity, resistance, and cost… a rare opportunity to support a technology with both transformative clinical impact and scalable market potential.”